Clinical Trial Update: Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing once-weekly exenatide to metformin, a DPP-4 inhibitor, or a thiazolidinedione as initial monotherapy in drug-naive type 2 diabetes pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Actos (pioglitazone) (pioglitazone)
• Byetta (exenatide) (exenatide)
• Januvia (sitagliptin) (sitagliptin)
• metformin (metformin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2012-11-26